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Botulinum toxin A improves involuntary limb
movements in Rasmussen syndrome
Dora A. Lozsadi, DPhil, MRCP; Ian K. Hart, FRCP; and
A. Peter Moore, FRCP
Rasmussen syndrome (RS) is a focal, progressive, cortical inflam-
mation affecting one cerebral hemisphere that usually presents
with epilepsia partialis continua (EPC) that is resistant to antiepi-
leptic drugs (AEDs). The encephalitis is often associated with
ipsilateral cerebral hemisphere and basal ganglia atrophy.1 Pa-
tients can develop involuntary movements, including myoclonus,
dystonia, and athetosis, usually in association with EPC.2 The
encephalitis is probably autoimmune mediated, although the
pathogenesis of the atrophy is unknown.3 We report a man with
established RS who developed EPC and painful dystonia that
improved with botulinum toxin A (BTX-A).
Case report. We described previously this 43-year-old, left-
handed man.4 He sought treatment in 1989 for EPC followed by
neurologic and cognitive deficits. The following therapies had no
sustained effect: multiple AEDs, right corticectomy in 1990, infu-
sions of sodium valproate or benzodiazepines into the corticectomy
cavity in 1994, and right frontoparietal subcortical transection in
1995. Immunomodulatory therapy started in 1996, and his condi-
tion improved, although he continued to have intermittent bouts
of left upper limb myoclonic jerking.4
He was stable until 2002 when he had several Klebsiella pneu-
moniae bacteremias. Frequent complex partial seizures (CPSs)
developed, and EPC returned with continuous myoclonic jerking
of the left upper limb and frequent, painful, dystonic, flexor
spasms of the left fingers, wrist, and elbow, which sometimes
spread to the shoulder. Although the CPS remitted with IV anti-
biotics and increasing his AED regimen (topiramate, 800 mg/d;
phenytoin, 425 mg/d; levetiracetam, 3 g/d; and vigabatrin, 2 g/d),
his involuntary movements persisted. Clonazepam (20 mg/d), IV
midazolam boluses, and increasing prednisolone (1.5 mg/kg/d) and
IV immunoglobulin (hIVIg; 2 g/kg fortnightly) doses had no effect.
There was progressive atrophy of the remaining right cerebral
hemisphere, caudate nucleus, and thalamus on serial brain MRI
scans since 1993 (figure). However, there was no evidence of reac-
tivation of brain inflammation on either the MRI scans or serial
CSF analysis.
We tried freehand injections of BTX-A (Dysport, Ipsen, UK;
total dose, 1000 mouse units [MU]) into the most affected left
upper limb muscles (200 MU into biceps and flexor digitorum
superficialis; 100 MU into trapezius, brachioradialis, triceps,
flexor carpi radialis, and flexor digitorum profundus; and 50 MU
into flexor carpi ulnaris and the thenar muscles). Marked im-
Figure. Progressive right basal ganglia and thalamic atrophy on serial MRI brain scans in a man with Rasmussen syn-
drome. (A) MRI brain scan in 1993, 3 years after right central sulcus lesionectomy. There is extensive high T2-weighted
signal in the right hemisphere and normal basal ganglia and thalamus. (B) MRI brain scan in 1996 just before the start
of immunomodulatory treatment. There is marked right hemisphere and basal ganglia atrophy. (C) MRI brain scan in
2002 at the onset of left upper limb myoclonus and dystonia. Right hemisphere and basal ganglia atrophy has
progressed.
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provement of his involuntary movements began 1 week later. His
painful spasms resolved over 2 weeks; the jerking became inter-
mittent; and useful limb function returned. His dose of topiramate
was reduced to 400 mg/d; phenytoin was reduced to 350 mg/d;
vigabatrin was reduced to 750 mg/d; and clonazepam was reduced
to 2 mg/d. After 5 months, his involuntary movements reappeared.
Additional BTX-A injections into the affected muscles (total dose,
500 MU) reproduced the effects of the first treatment.
Discussion. Repeated BTX-A injections were an effective
treatment for our patient’s late-onset, limb dystonia and continu-
ous myoclonic jerking. Changes in the ipsilateral basal ganglia in
association with cerebral hemisphere abnormalities are common
in patients with RS and usually appear early in the course of the
syndrome. In one serial MRI study, eight of eight patients with RS
had atrophy of the head of the caudate nucleus at 4 months after
onset of symptoms.1 In another patient, atrophy of the right cau-
date, globus pallidus, and putamen and mild increased T2-
weighted signal in the right striatum were the only MRI brain
scan findings at presentation.5 However, no additional EPC-
associated involuntary movements were described in any of these
patients, and reports of hyperkinetic movements other than myoc-
lonus are rare in EPC associated with RS.2 When these move-
ments occur, they start typically at the onset or early in the course
of the syndrome.2 By contrast, our patient’s involuntary move-
ments started 14 years after the clinical onset of RS when there
was established caudate atrophy. Human IVIg improved atheto-
sis, dystonia, and EPC in one woman with RS, although the re-
sponse was short lasting.2 Increasing the doses of prednisolone
and hIVIg had no effect on our patient’s involuntary movements.
Our patient’s repeated response to BTX-A contrasts with the
reports of its ineffectiveness in two patients with EPC and in two
children with RS and EPC.6,7 These previous findings suggest that
uncomplicated EPC may be resistant to this therapy. However, it
can be difficult clinically to distinguish the recurrent, simple focal
motor seizures of EPC from the other hyperkinetic movements,
especially myoclonus, occurring in patients with established RS.
We propose that BTX-A can be a useful, long-term therapy for
involuntary, hyperkinetic movements in RS and that it should be
considered especially for those patients with late-onset, focal
movements that do not respond to conventional AED treatment or
immunotherapy.
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